The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes

Annals of Pharmacotherapy

Volumn 33, Issue 6, 1999, Pages 712-722

  Stringer, Kathleen A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Abciximab; Acute coronary syndromes; Eptifibatide; Glycoprotein IIb IIIa platelet inhibitors; Thrombus formation; Tirofiban

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; PROSTAGLANDIN SYNTHASE INHIBITOR; TICLOPIDINE; TIROFIBAN; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; BLEEDING; CLINICAL TRIAL; CORONARY STENT; DRUG EFFICACY; HEART MUSCLE ISCHEMIA; HUMAN; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOGENESIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ANIMALS; BLOOD PLATELETS; CORONARY DISEASE; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0033064639     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18327     Document Type: Review

References (53)

1. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q wave myocardial infarction. Circulation 1998;97:1195-206.
2. Braunwald E, Mark DB, Jones RH, Cheitlin MD, Fuster V, McCauley KM, et al. Unstable angina: diagnosis and management. Clinical Practice Guideline No. 10. Rockville, MD: Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, US Department of Health and Human Services, 1994.
3. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
4. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-30.
5. Braunwald E, Jones RH, Mark DB, Brown J, Brown L, Cheitlin MD, et al. Diagnosing and managing unstable angina. Circulation 1994;90:613-22.
6. Rizik DG, Healy S, Margulis A, Vandam D, Bakalyar D, Timmis G, et al. A new classification for hospital prognosis of unstable angina pectoris. Am J Cardiol 1995;75:993-7.
7. Braunwald E. Unstable angina: a classification. Circulation 1989;80:410-4.
8. Zareba W, Moss AJ, Raubertas RF. Risk of subsequent cardiac events in stable convalescing patients after non-Q-wave versus Q-wave myocardial infarction. Coron Artery Dis 1994;5:1009-18.
9. Anderson HV, Cannon CP, Stone PH, Williams DO, McCabe CH, Knatterud GL, et al. One year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 1995;26:1643-50.
10. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
11. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
12. Boden WE, O'Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med 1998;338:1785-92.
13. Patrono C, Renda G. Platelet activation and inhibition in unstable coronary syndromes. Am J Cardiol 1997;80(suppl 5A):17E-20E.
14. Lefkovits J, Plow EF, Topol ET. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
15. Smyth SS, Joneckis CC, Parise LV. Regulation of vascular integrins. Blood 1993;81:282743.
16. Ginsberg MH, Xiaoping D, O'Toole TE, Loftus JC, Plow EF. Platelet integrins. Thromb Haemost 1993;70:87-93.
17. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-94.
18. Coukell AJ, Markham A. Clopidogrel. Drugs 1997;54:745-50.
19. Schror K. Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel. Vase Med 1998;3:247-51.
20. Ellis SG, Bates ER, Schaible T, Weisman HF, Pitt B, Topol EJ. Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis. J Am Coll Cardiol 1991;17(suppl B):89B-95B.
21. Adgey AAJ. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Am Heart J 1998;135(suppl):S43-55.
22. Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, et al. Aspirin, heparin, or both to treat unstable angina. N Engl J Med 1988;319: 1105-11.
23. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA 1996;276:811-5.
24. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Richard P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both or neither. BMJ 1998;316:1337-43.
25. Cairns JA, Lewis HD, Meade TW, Sutton GC, Theroux P. Antithrombotic agents in coronary artery disease. Chest 1995;108(suppl):380S-400S.
26. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
27. Faulds D, Sorkin EM. Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischemic heart disease. Drugs 1994; 48:583-98.
28. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757-64.
29. Mascelli MA, Lance ET, Jordan RE. Pharmacodynamic profile of shortterm abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998;97:1680-8.
30. 2 fragments of murine antibody 7E3 directed against human glycoprotein IIb/IIIa in patients with unstable angina. J Clin Invest 1990;86:651-9.
31. Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP. Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. Am J Cardiol 1996;78:1161-3.
32. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S. et al., on behalf of the EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at 6 months. Lancet 1994;343:81-6.
33. Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complications. JAMA 1997;278:479-84.
34. Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, et al., for the EPIC Investigators. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995; 91:2882-90.
35. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
36. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasry-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
37. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997;80(suppl):11B-20B.
38. The IMPACT II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Lancet 1997;349:1422-8.
39. 2+ on GP IIb-IIIa interactions with Integrelin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96:1488-94.
40. Harrington RA. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Am J Cardiol 1997;80(suppl):34B-8B.
41. Mousa SA, Bozarth JM, Lorelli W, Forsythe MS, Thoolen MJ, Slee AM, et al. Antiplatelet efficacy of XV459, a novel nonpeptide platelet GP IIb/IIIa antagonist: comparative platelet binding profiles with c7E3. J Pharmacol Exp Ther 1998;286:1277-84.
42. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
43. Gibson CM, Goel M, Cohen DJ, Piana RN, Deckelbaum LI, Harris KE, et al. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. J Am Coll Cardiol 1998;32:28-34.
44. The PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338: 1498-505.
45. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
46. Chesebro JH, Badiman JJ. Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease. N Engl J Med 1998;338:1539-40.
47. Giugliano RP, Hyatt RR. Thrombocytopenia with GP IIb/IIIa inhibitors: a meta-analysis. Abstracts from the American College of Cardiology Meeting, Atlanta, GA, March 29-April 11, 1998 (CD-ROM). Conifer Information Systems, Belle Head, NJ, 1998: abstract no. 837-5.
48. Braunwald E, Maseri A, Armstrong PW, Califf RM, Gibler WB. Hamm CW, et al. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. Am Heart J 1998;135(suppl):S56-66.
49. Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98:2829-35.
50. Willerson JT. Inhibitors of platelet glycoprotein IIb/IIIa receptors: will they be useful when given chronically? Circulation 1996;94:866-8.
51. Theroux P. Oral inhibitors of platelet membrane receptor glycoprotein IIb/IIIa in clinical cardiology: issues and opportunities. Am Heart J 1998; 135(suppl):S107-12.
52. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation 1987;76:142-54.
53. Mark DB, Talley JD, Topol EJ, Bowman L, Lam LC, Anderson KM, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation 1996;94:629-35.